Dose-Dependent GI Side Effects Studies show that gastrointestinal side effects are most frequent and intense during the early stages of GLP-1 receptor agonist therapy and are largely dose-dependent. This isnt a sign that the medication is harming the body
It may cause pain, erectile dysfunction, or make intimacy difficult
L- ( 500 )
7 Conclusion and Future Directions This review aims to provide an overview and update on the pathogenesis, reported precipitating factors, genetic risk factors, presentation, diagnosis, and management of SJS/TEN
Figutumumab has also been tested in phase I (NCT00635245 and NCT01536145) and phase II (NCT00372996) clinical trials against BrCa with apparently negative unpublished results
Safety Information: Always consult with a healthcare professional before starting any new treatment, especially if you have pre-existing health conditions or are taking other medications